Forte Biosciences
FBRX
80 hedge funds and large institutions have $69.7M invested in Forte Biosciences in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
53% more call options, than puts
Call options by funds: $323K | Put options by funds: $211K
27% more funds holding
Funds holding: 63 → 80 (+17)
0.02% more ownership
Funds ownership: 0.08% → 0.1% (+0.02%)
24% less capital invested
Capital invested by funds: $92M → $69.7M (-$22.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$5.93M |
| 2 |
Citigroup
New York
|
+$4.99M |
| 3 |
6CM
683 Capital Management
New York
|
+$3.73M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.87M |
| 5 |
Axa
Paris,
France
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.5M |
| 2 |
Millennium Management
New York
|
-$616K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$349K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$211K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $8K | – | – | – |
|
77
Acadian Asset Management
Boston,
Massachusetts
| $5K | +$8.61K | +2 | New |
|
|
FHA
78
Flagship Harbor Advisors
Boston,
Massachusetts
| $4K | +$4.31K | +1 | New |
|
79
Bank of Montreal
Toronto,
Ontario, Canada
| $2K | +$4.31K | +1 | New |
|
80
Barclays
London,
United Kingdom
| $1K | -$77.5K | -18 | Closed |
|
81
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
PCM
82
Prelude Capital Management
New York
| $1K | – | – | – |
|
|
SWM
83
SeaCrest Wealth Management
Purchase,
New York
| $1K | – | – | – |
|
|
GT
84
Glenmede Trust
Philadelphia,
Pennsylvania
| $314 | +$439K | +102 | New |
|
85
BNP Paribas Financial Markets
Paris,
France
| $49 | -$8.61K | -2 | Closed |
|
|
86
Fidelity Investments
Boston,
Massachusetts
| – | -$5.5M | -941 | Closed |
|
|
87
ProShare Advisors
Bethesda,
Maryland
| – | -$161K | -28 | Closed |
|
|
GP
88
Girard Partners
King Of Prussia,
Pennsylvania
| – | -$15K | -3 | Closed |
|
|
IP
89
Isthmus Partners
Madison,
Wisconsin
| – | -$8K | -1 | Closed |
|
90
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -1 | Closed |
|
FBRX Hedge Fund Activity: Q4 2018 in Review
80 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2018, worth a combined $69.7M — down 24% from $92M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FBRX positions and 7 closed out — a net gain of 17 holders — while 28 added to existing stakes and 10 trimmed.
The largest buyer was Foresite Capital Management III, adding an estimated $5.93M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.5M sold.
- 80 institutional investors held Forte Biosciences (FBRX) as of Q4 2018, up from 63 in Q3 2018.
- Funds reported $69.7M of Forte Biosciences stock for Q4 2018, down 24% quarter-over-quarter.
- 24 funds opened new Forte Biosciences positions in Q4 2018 and 7 closed out, a net change of +17 holders.
- The largest Forte Biosciences buyer in Q4 2018 was Foresite Capital Management III, an estimated $5.93M added.
- The largest Forte Biosciences seller in Q4 2018 was Fidelity Investments, an estimated $5.5M sold.
Based on aggregated 13F filings for Q4 2018.